UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

UCLA Rheumatology

Print
Email
Share

Research and Clinical Trials

UCLA Division of Rheumatology conducts cutting-edge biomedical and health-related research studies that include both interventional and observational studies.  Our clinical studies are sponsored/funded by National Institute of Health (NIH), pharmaceutical companies, and/or non-profit medical institutions/organizations.

Treatment/Interventional studies are those in which the research subjects are assigned to a treatment or intervention and their outcomes are measured.

Observational studies are those in which individuals are observed and their outcomes are measured by the study investigators.

Current Clinical Trials

Rheumatoid Arthritis
Cholesterol
Lupus
Scleroderma

If you would like to get more information on any studies please call us at (310) 825-0096 or email rheumresearch@mednet.ucla.edu.

If you are interested in finding out more information of a particular study, please contact the study personnel.

Study Type

Title of Study

 

Rheumatoid Arthritis

Observational Biomarkers in Rheumatoid Arthritis (Investigatory)

Status: Recruiting

Principal Investigator
Veena Ranganath,MD

 For more information, contact
310-825-0096

Treatment

A3921024: A Long Term, Open Label, Follow Up Study of Tafocitinib (CP 690,550) For Treatment of Rheumatoid Arthritis

Status: Closed for Enrollment

 Principal Investigator
Christina Charles, MD


For more information contact
Maricela Rodriguez
(310)794-9504

Treatment

Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis. 1 year study  

Status: Closed for Enrollment

 Principal Investigator
Veena Ranganath, MD

 

Treatment/
Interventional
*Multiple studies

Principal Investigators
Daniel Furst, MD; Christina Charles-Schoeman, MD; Veena Ranganath, MD

For more information contact 310-825-0096 

Cholesterol
Observational HDL Function in Patients With and Without Rheumatic Disease (Investigatory)

Principal Investigators
Christina Charles-Schoeman, MD

For more information contact,
310-825-0096
Lupus
Observational Influence of DMARD Therapies for SLE on Levels of Pro-Inflammatory HDL Status: Recruiting Principal Investigator
Bevra Hahn, MD

For more information contact
Maureen McMahon, MD, MS

 Treatment

Epratuzumab vs Placebo-

Phase 3 trial. Epratuzumab is a humanized monoclonal antibody of IgG class which specifically binds to CD22.

Status: Recruiting

Principal Investigators
Jennifer Grossman, MD
Maureen McMahon, MD

For more information contact
Elizabeth Geledzhyan
310-825-6461

Treatment

Illuminate-LY2127399 vs Placebo

Phase 3 trial. LY2127399 is a human immunoglobulin G subclass 4-variant monoclonal antibody that neutralizes BAFF (like a subcutaneuos version of belimumab).  

Status: Recruiting

 Principal Investigators
Jennifer Grossman, MD
Maureen McMahon, MD

For more information contact
Elizabeth Geledzhyan
310-825-6461

Treatment PF-04236921 vs Placebo

Phase 2 study. PF-04236921 is a fully human antibody of the immunoglobulin G that binds to IL-6.

Status: Recruiting

Principal Investigators
Jennifer Grossman, MD
Maureen McMahon, MD

For more information contact
Elizabeth Geledzhyan
310-825-6461

Treatment

 MEDI-545 vs Placebo

Phase 2 study. Medi-546 is a human immunoglobulin G1 kappa directed against Interferon alpha.

Status: Recruiting

Principal Investigators
Jennifer Grossman, MD
Maureen McMahon, MD

For more information contact
Elizabeth Geledzhyan
310-825-6461

Observational Lupus Genetics 

Status: Recruiting

Principal Investigator
Betty P. Tsao, PhD 

For more information contact
Erika Magdangal

310-825-2230

 

Observational Biomarkers in Lupus

Status: Recruiting
Principal Investigator
Ram Raj Singh, MD

For more information contact
Ram Raj Singh, MD
Observational The Role of Gender Factors in Lupus and Autoimmunity

Status: Recruiting
Principal Investigator
Ram Raj Singh, MD

For more information contact
Ram Raj Singh, MD

Observational Autoimmunity Characteristics in Patients with Systemic Lupus Erythematosus versus Health Controals 

Status: Recruiting

Principal Investigator
Jennifer King, MD 

For more information contact
Jennifer King, MD 

Observational Observational, Mechanisms of Inflammation and Immune Response in Skin Dermatoses.

Status: Recruiting

Principal Investigator
Jennifer King, MD

For more information contact
Jennifer King, MD 

Treatment/
Interventional
*Multiple studies

Status: Recruiting
Principal Investigators
Jennifer Grossman, MD; Maureen McMahon, MD

Scleroderma    
 Treatment/
Interventional
*Multiple studies

Principal Investigator
Daniel Furst, MD 

 

 

Treatment

DUAL-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis

Status: Closed for Enrollment

Principal Investigators
Daniel Furst, MD
Philip Clements, MD

For more information contact
Maricela Rodriguez
(310)794-9504

 

 Treatment

 WA27788: A PHASE II/III, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO
IN PATIENTS WITH SYSTEMIC SCLEROSIS

Status: Closed for Enrollment

                                                                                    

Principal Investigator
Daniel Furst, MD 

 

Treatment

 SLSII: Mycophenolate vs Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease

Status: Closed for Enrollment

Principal Investigator
Donald Tashkin, MD


For more information contact
Maricela Rodriguez
(310)794-9504

 

Other

GWAS: Two Stage Genome-Wide Association Study in Systemic Sclerosis

Status: Closed for Enrollment

 

Principal Investigators
Daniel Furst, MD
Philip Clements, MD

 

Other

 PHAROS: Outcome Studies in Systemic Sclerosis: A Prospective Database of Echocardiograms and PFTs on Patients with Limited Scleroderma (Standard of Care)

Status: Recruiting

 

Principal Investigators
Daniel Furst, MD
Philip Clements, MD

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

UCLA Rated One of the Top Hospitals in the Nation